证券代码：688366 证券简称：昊海生科 公告编号：2023-039 上海昊海生物科技股份有限公司 股东减持股份期限届满暨减持结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 1 6,151,186 股，占公司目前总股本 171,287,974 股的 3.5911%。本次减持计划实施 完毕，现将具体情况公告如下。 注：持股比例系占本次减持计划披露时公司总股本 171,271,000 股的比例。 上述减持主体无一致行动人。 2 重要内容提示： 股东持股的基本情况 上海昊海生物科技股份有限公司（以下简称"公司"）股东楼国梁先生于本 次减持计划实施前持有公司无限售条件流通股股份为 7,125,075 股，占减持计划 披露时公司总股本 171,271,000 股的 4.1601%。 上述股份来源于公司首次公开发行前，已于 2020 年 10 月 30 日解除限售并 上市流通。 减持计划的实施结果情况 公司于 2023 年 2 月 18 日披露了《上海昊海生物科技股份有限公司股东减持 股份计划公告》（公告编号： ...

根据《中华人民共和国公司法》（以下简称"《公司法》"）等法律、法规及《上 海昊海生物科技股份有限公司章程》（以下简称"《公司章程》"）的相关规定，我 们作为公司的独立董事，在认真审阅有关文件资料后，对公司第五届董事会第十 四次会议相关事项，发表如下独立意见： 一、《关于以集中竞价交易方式回购公司 A 股股份方案的议案》的独立意 见 1、本次回购股份方案符合《公司法》《中华人民共和国证券法》《上市公 司股份回购规则》《上海证券交易所上市公司自律监管指引第7号——回购股份》 等法律法规、规范性文件及《公司章程》的相关规定，审议该事项的董事会会议 表决程序符合相关法律法规和《公司章程》的相关规定。 上海昊海生物科技股份有限公司独立董事 关于第五届董事会第十四次会议相关事项的独立意见 上海昊海生物科技股份有限公司（以下简称"公司"）于 2023 年 8 月 24 日 召开公司第五届董事会第十四次会议（以下简称"会议"），会议审议了《关于以 集中竞价交易方式回购公司 A 股股份方案的议案》等议案。 4、本次回购以集中竞价交易方式实施，不存在损害公司及全体股东，特别 是中小股东利益的情形。 综上，独立董事认为公司本次回购 ...

证券代码：688366 证券简称：昊海生科 公告编号：2023-038 上海昊海生物科技股份有限公司 关于以集中竞价交易方式回购公司A股股份方案的公告 1、 拟回购股份的用途：回购的股份将在未来适宜时机全部用于员工持股计 划及/或股权激励，并在股份回购实施结果暨股份变动公告后三年内予以转让， 若未能在前述期间内转让完毕，则将依法履行相关程序予以注销并减少注册资本； 2、 回购方式：上海证券交易所交易系统集中竞价交易； 3、 回购期限：自股东大会审议通过本次回购方案之日起 12 个月内； 4、 回购价格：不超过人民币 130.00 元/股（含）； 5、 拟回购股份的资金总额：不低于人民币 10,000.00 万元（含），不超过人 民币 20,000.00 万元（含）。 ● 本次回购资金来源为公司自有资金。 ● 相关股东是否存在减持计划： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 上海昊海生物科技股份有限公司（以下简称"公司"）本次以集中竞价 交易方式拟回购部分公司已发行的人民币普通股（A 股）股票， ...

第五届董事会第十四次会议决议公告 证券代码：688366 证券简称：昊海生科 公告编号：2023-037 上海昊海生物科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海昊海生物科技股份有限公司（以下简称"公司"）第五届董事会第十四 次会议（以下简称"本次会议"）于2023年8月24日13:30时以现场结合通讯方式 召开，本次会议通知已于2023年8月21日以书面方式送达公司全体董事。本次会 议由董事长侯永泰先生主持，会议应参加董事11人，实际参加董事11人。本次会 议的召集、召开符合《中华人民共和国公司法》（以下简称"《公司法》"）等 法律、法规和《上海昊海生物科技股份有限公司章程》（以下简称"《公司章程》"） 的有关规定。 1.1 拟回购股份的种类 本次回购股份的种类为公司发行的人民币普通股（A股）股票。 表决情况：11票同意，0票反对，0票弃权 1.2 拟回购股份的方式 通过上海证券交易所交易系统以集中竞价交易方式回购。 二、董事会会议审议情况 经与会董事审议，做出以下决议： ...

Financial Performance - The company's total assets reached RMB 7,254.17 million, and net assets attributable to shareholders increased by RMB 1,949.07 million compared to the end of 2022[6]. - The company reported a 35.66% increase in overall revenue, attributed to the normalization of operations after previous disruptions[15]. - The company's operating revenue for the reporting period reached approximately RMB 1.31 billion, representing a year-on-year increase of 35.66%[49]. - The company reported a revenue of CNY 1.5 billion for the first half of 2023, representing a year-over-year increase of 25%[160]. - The net profit attributable to shareholders of the listed company increased by 188.94% year-on-year, amounting to approximately CNY 205.23 million[169]. - The basic earnings per share (EPS) rose to CNY 1.20, reflecting a 192.68% increase compared to the previous year[164]. - The gross margin for the first half of 2023 improved to 45%, up from 40% in the previous year[160]. - The net cash flow from operating activities increased by 147.44% year-on-year, primarily driven by significant growth in operating revenue[38]. - The company's R&D investment accounted for 7.72% of operating revenue, slightly down by 0.21 percentage points from the previous year[164]. Revenue Breakdown - Revenue from the myopia prevention and refractive correction product line was RMB 206.06 million, a year-on-year increase of 16.36%[7]. - Revenue from optical materials business was RMB 110.38 million, up 42.21% year-on-year, benefiting from the recovery of global operations[7]. - Revenue from cataract products reached RMB 259.62 million, a significant increase of 55.20% year-on-year, driven by the rapid recovery of cataract surgeries[18]. - Revenue from medical beauty and wound care products was RMB 484.87 million, an increase of 47.49% year-on-year[28]. - The revenue from the orthopedic product line was RMB 231.83 million, a year-on-year increase of 29.74%[42]. - The revenue from anti-adhesion and hemostatic products was RMB 90.74 million, reflecting a year-on-year growth of 7.87%[43]. - The company's hyaluronic acid products achieved sales revenue of RMB 255.96 million, an increase of RMB 136.55 million compared to the same period last year, representing a growth rate of 114.35%[56]. - The third-generation hyaluronic acid product "Haimi" generated sales revenue exceeding RMB 115 million, with a year-on-year growth of 377.37%[58]. - The medical chitosan product for intra-articular injection saw revenue growth of 60.77%, with sales reaching RMB 80.82 million compared to RMB 50.27 million in the previous year[60]. Market Position and Share - The company’s market share in the anti-adhesion materials segment was 29.90%, making it the largest supplier in China[43]. - The company holds a 46.54% market share in the domestic orthopedic joint injection product market, maintaining its position as the leading manufacturer for nine consecutive years[61]. - The market for external epidermal growth factor products in China was approximately CNY 823 million in 2022, projected to grow to CNY 1.813 billion by 2027, with a compound annual growth rate of about 17.11%[196]. - The company is the largest domestic producer of surgical adhesion prevention agents and a major producer of medical collagen sponge, enhancing surgical safety and recovery[185]. - The company is the largest domestic producer of orthopedic joint cavity viscoelastic supplements, addressing common degenerative joint diseases in the elderly[190]. Research and Development - The company plans to focus on the clinical trials of several innovative products, including hydrophobic aspheric toric intraocular lenses and the second-generation PRL products in the second half of 2023[32]. - Research and development expenses increased by 32.17% to RMB 101.39 million, indicating a focus on innovation[49]. - The company is investing CNY 500 million in R&D for new biopharmaceutical technologies over the next two years[160]. - The group has increased R&D investment during the reporting period to develop new technologies and products, as well as to transform core technological achievements[199]. - The company is advancing clinical trials for a new biological gel product aimed at treating retinal detachment[173]. Environmental Commitment - The environmental pollution discharge from the company and its subsidiary, Likangrui, did not exceed the standard limits during the reporting period[76]. - The company has established a water reuse system to enhance water resource utilization efficiency[95]. - The company has obtained ISO 14001 environmental management system certification, demonstrating its commitment to sustainable development[108]. - The company has implemented continuous online monitoring of major pollutants in wastewater and waste gas, ensuring compliance with environmental regulations[107]. - The company has set carbon emission reduction targets and is actively seeking ways to optimize resource usage through facility upgrades and process improvements[95]. Corporate Governance and Compliance - The company held its annual general meeting on June 12, 2023, where several key resolutions were passed, including the approval of the 2022 financial statements[80]. - The company’s board of directors was authorized to repurchase H shares during the first A-share and H-share shareholder meetings held on June 12, 2023[80]. - The semi-annual report has not been audited, ensuring transparency in financial reporting[140]. - The management has highlighted the importance of risk factors in the report, advising investors to be cautious[136]. - There are no significant risks or violations related to non-operational fund occupation by controlling shareholders or related parties[139].

Financial Performance - The company recorded a revenue of approximately RMB 1,305.71 million for the six months ended June 30, 2023, representing an increase of approximately RMB 349.44 million or 36.54% compared to the same period in 2022[1]. - Profit attributable to equity holders of the company was approximately RMB 205.24 million, a significant increase of approximately RMB 134.21 million or 188.94% compared to RMB 71.03 million in the same period last year[1]. - Basic earnings per share for the period were RMB 1.20, compared to RMB 0.41 in the same period of 2022[3]. - Gross profit for the period was RMB 926.42 million, compared to RMB 666.78 million in the same period of 2022, reflecting a strong growth in profitability[2]. - The overall gross profit margin increased to 70.95% in the reporting period, up from 69.73% in the previous year, driven by the rising revenue from hyaluronic acid products[37]. Research and Development - Research and development expenses amounted to approximately RMB 101.39 million, an increase of approximately RMB 24.68 million or 32.17% year-on-year, accounting for 7.77% of total revenue[1]. - The company is engaged in research and development of biopharmaceuticals and related services, indicating ongoing innovation efforts[7]. - R&D expenses for the period were RMB 101,391 thousand, representing a 32.2% increase compared to RMB 76,711 thousand in the same period last year[19]. - The company is focusing on expanding its ophthalmic and medical aesthetic product lines, with several key R&D projects progressing smoothly, including the registration of innovative products[38]. Assets and Liabilities - The total value of non-current assets as of June 30, 2023, was RMB 3,375.60 million, slightly up from RMB 3,360.28 million at the end of 2022[4]. - Current assets totaled RMB 3,878.57 million, an increase from RMB 3,532.12 million at the end of 2022[4]. - The company reported a net asset value of RMB 6,090.57 million as of June 30, 2023, compared to RMB 5,902.38 million at the end of 2022[5]. - Total current liabilities were approximately RMB 657.79 million, an increase of about RMB 146.51 million or 28.66% from the end of 2022, primarily due to increased dividend payables[66]. - The company's total liabilities were approximately RMB 1,163.60 million, with a debt-to-asset ratio of 16.04%, up from 14.36% at the end of 2022[71]. Market and Revenue Breakdown - Revenue from mainland China was RMB 1,059,733,000, up 34.5% from RMB 787,631,000 year-on-year[13]. - Revenue from ophthalmic products was RMB 479,149 thousand, up 35.4% from RMB 354,161 thousand year-on-year[15]. - Revenue from medical beauty and wound care products increased to RMB 483,499 thousand, a 47.8% rise from RMB 327,057 thousand in the previous year[15]. - The company continues to expand its market presence, with revenue contributions from Europe, the United States, and other regions increasing significantly[13]. Shareholder Actions - The company did not recommend the payment of an interim dividend for the six months ended June 30, 2023[1]. - The company repurchased 575,900 H shares during the reporting period, which were subsequently canceled on June 16, 2023[7]. - The company issued 592,874 A shares under the 2021 A-share restricted stock incentive plan during the reporting period[7]. Future Outlook and Strategy - The company plans to focus on four rapidly developing treatment areas: ophthalmology, medical aesthetics, wound care, and orthopedics, emphasizing research and innovation[57]. - In the second half of 2023, the company aims to enhance integration of acquired businesses to maximize operational efficiency and core competitiveness[58]. - The company will continue to advance the clinical trials of key innovative products, including various types of intraocular lenses and myopia control products[58]. - The company is set to strengthen its brand presence in the medical aesthetics sector, particularly for its high-end hyaluronic acid products[59].

一、监事会会议召开情况 上海昊海生物科技股份有限公司（以下简称"公司"）第五届监事会第九次 会议（以下简称"本次会议"）于2023年8月17日15:30时以现场结合通讯方式召 开，本次会议通知已于2023年8月3日以书面方式送达公司全体监事。本次会议由 监事会主席刘远中先生主持，会议应参加监事5人，实际参加监事5人。本次会议 的召集、召开符合《中华人民共和国公司法》等法律、法规和《上海昊海生物科 技股份有限公司章程》（以下简称"《公司章程》"）的有关规定。 证券代码：688366 证券简称：昊海生科 公告编号：2023-035 上海昊海生物科技股份有限公司 第五届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 二、监事会会议审议情况 经与会监事审议，做出以下决议： 1.审议通过《关于公司截至2023年6月30日止半年度财务报表的议案》 表决情况：5票同意，0票反对，0票弃权 财 务 报 表 具 体 情 况 请 见 公 司 于 同 日 在 上 海 证 券 交 易 所 网 站 (http://www. ...

证券代码：688366 证券简称：昊海生科 公告编号：2023-034 上海昊海生物科技股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 募集资金基本情况 （一）实际募集资金金额、资金到账时间 上海昊海生物科技股份有限公司（以下简称"公司"或"本公司"）经中国证 券监督管理委员会证监许可[2019]1793号文同意，由主承销商瑞银证券有限责任公 司采用向战略投资者定向配售、网下向符合条件的投资者询价配售、网上向持有上 海市场非限售Ａ股股份和非限售存托凭证市值的社会公众投资者定价发行相结合 的方式进行，向社会公开发行了人民币普通股（A股）股票17,800,000股，发行价为 每股人民币89.23元，共计募集资金总额为人民币1,588,294,000.00元，扣除券商承 销佣金及保荐费人民币46,450,107.55元和增值税2,787,006.45元后，主承销商瑞银证 券有限责任公司于2019年10月25日汇入公司募集资金监管账户中国光大银行股份 有限 ...

证券代码：688366 证券简称：昊海生科 公告编号：2023-036 上海昊海生物科技股份有限公司 关于收到公司董事长提议回购公司股份的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海昊海生物科技股份有限公司（以下简称"公司"）于2023年8月17日收 到公司董事长侯永泰先生《关于提议上海昊海生物科技股份有限公司回购公司股 份的函》。提议内容主要如下： 一、提议人提议回购股份的原因和目的 侯永泰先生基于对公司未来持续发展的信心和对公司价值的认可，为了维护 广大投资者利益，增强投资者对公司的投资信心，同时促进公司稳定健康发展， 有效地将股东利益、公司利益和员工利益紧密结合在一起，提议公司通过集中竞 价交易方式进行股份回购。回购的股份将在未来合适时机全部用于员工持股计划 及/或股权激励计划。 二、提议人的提议内容 1、回购股份的种类：公司发行的人民币普通股（A股）股票。 2023年5月5日，公司完成2021年A股限制性股票激励计划第一个归属期第一 批次的归属登记，侯永泰先生归属股份数量为2.4260万股。除上 ...

上海昊海生物科技股份有限公司独立董事 关于第五届董事会第十三次会议相关事项的独立意见 我们作为上海昊海生物科技股份有限公司（以下简称"公司"）的独立董事， 根据《中华人民共和国公司法》等法律法规及《上海昊海生物科技股份有限公司 章程》的相关规定，基于独立、客观判断的原则，在认真审阅公司相关材料并听 取有关说明后，对公司第五届董事会第十三次会议审议的《关于公司 2023 年半 年度募集资金存放与实际使用情况的专项报告的议案》，发表如下独立意见： 上海昊海生物科技股份有限公司 2023 年 8 月 17 日 经审查，报告期内，公司募集资金的实际存放、使用情况与公司信息披露一 致，符合《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》及公 司《募集资金管理制度》的相关规定，公司不存在违规使用和存放募集资金的行 为，亦不存在改变或变相改变募集资金投资项目及损害股东利益的情况。我们同 意《关于公司 2023 年半年度募集资金存放与实际使用情况的专项报告的议案》。 独立董事：郭永清、苏治、赵磊、姜志宏、杨玉社 ...